Preclinical relevance of dosing time for the therapeutic index of gemcitabine-cisplatin

British Journal of Cancer

Volumn 92, Issue 9, 2005, Pages 1684-1689

  Li, X M ^a   Tanaka, K ^a,b   Sun, J ^a,c   Filipski, E ^a   Kayitalire, L ^d   Focan, C ^e   Levi F ^a  

^a INSERM   (France)

^b YOKOHAMA CITY UNIVERSITY HOSPITAL   (Japan)

^c SUN YAT SEN UNIVERSITY   (China)

^d ELI LILLY AND COMPANY   (United States)

^e EORTC DATA CENTER   (Belgium)

Author keywords

Chronopharmacology; Cisplatin; Gemcitabine; Glasgow osteosarcoma; Mice

Indexed keywords

CISPLATIN; GEMCITABINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHRONOPHARMACOLOGY; CIRCADIAN RHYTHM; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG DELIVERY SYSTEM; DRUG TOLERABILITY; GLASGOW COMA SCALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CIRCADIAN RHYTHM; CISPLATIN; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; MALE; MICE; MICE, INBRED C57BL; OSTEOSARCOMA;

EID: 19944411802     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602564     Document Type: Article

References (44)

1. Abratt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D, Rugg TA (1994) Efficacy and safety profile of gemcitabine in non-small cell lung cancer: a phase II study. J Clin Oncol 12: 1535-1540
2. Bélanger PM, Desgagne M, Bruguerolle B (1988) Circadian periodicity in the glutathione concentration of rat liver. Annu Rev Chronopharmacol 5: 215-218
3. Braakhuis BJ, Ruiz Van Haperen VWT, Boven E, Veerman G, Peters GJ (1995) Schedule-dependent antitumor effect of gemcitabine in vivo model systems. Semin Oncol 22(suppl 11): 42-46
4. Carmichael J, Fink U, Russell RCG, Spittle MF, Harris AL, Spiessi G, Blatter J (1996) Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 73: 101-105
5. Carmichael J, Possinger K, Phillip P, Beykirch M, Kerr H, Walling J, Harris AL (1995) Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol 13: 2731-2736
6. De Pas T, Curigliano G, Franceschelli L, Catania C, Spaggiari L, de Braud F (2001) Gemcitabine-induced systemic capillary leak syndrome. Ann Oncol 12: 1651-1652
7. Filipski E, Amat S, Lemaigre G, Vincenti M, Breillout F, Lévi F (1999) Relationship between circadian rhythm of vinorelbine toxicity and efficacy in P388-bearing mice. J Pharmacol Exp Therap 289: 231-235
8. Filipski E, Delaunay F, King VM, Wu MW, Claustrat B, Grechez-Cassiau A, Guettier C, Hastings MH, Francis L (2004) Effects of chronic jet lag on tumor progression in mice. Cancer Res 64: 7879-7885
9. Filipski E, Innominato PF, Wu MW, Li XM, Iacobeli S, Xian LJ, Lévi F (2005) Effects of light and food schedules on liver and tumor molecular clock. J Natl Cancer Inst 97: 507-517
10. Garufi C, Bjarnason GA, Giacchetti S, Innominato P, Focan F, Coudert B, Tubiana N, Waterhouse JM, Gorlia T, Lévi F (2005) Independent prognostic value of the rest/activity circadian rhythm on overall survival (OS) in patients (pts) with metastatic colorectal cancer (MCC) receiving first line chemotherapy with 5-fluorouracil, leucovorin and oxaliplatin: a companion study to EORTC 05963, Proceedings of the 41st Annual Meeting of the American Society of Clinical Oncolory, Florida, 2005 (Abstract 3553)
11. Giovannetti E, Mey V, Danesi R, Basolo F, Barachini S, Deri M, Del Tacca M (2005) Interaction between gemcitabine and topotecan in human non-small-cell lung cancer cells: effects on cell survival, cell cycle and pharmacogenetic profile. Br J Cancer 92: 681-689
12. Granda TG, D'attino RM, Filipski E, Vrignaud P, Garufi C, Terzoli E, Bissery MC, Lévi F (2002) Circadian optimisation of irinotecan and oxaliplatin efficacy in mice with Glasgow osteosarcoma. Br J Cancer 86: 999-1005
13. Granda TG, Filipski E, D'Attino RM, Vrignaud P, Anjo A, Bissery MC, Lévi F (2001) Experimental chronotherapy of mouse mammary adenocarcinoma MA13/C with docetaxel and doxorubicin as single agent and in combination. Cancer Res 61: 1996-2001
14. Granda TG, Lévi F (2002) Tumor-based rhythms of anticancer efficacy in experimental models. Chronobiol Int 19: 21-41
15. Granda TG, Liu XH, Smaaland R, Cermakian N, Filipski E, Sassone-Corsi P, Lévi F (2005) Circadian regulation of cell cycle and apoptosis proteins in mouse bone marrow and tumor. FASEB 19: 304-306
16. Hao XS, Hao JH, Liu FT, Newland AC, Jia L (2003) Potential mechanisms of leukemia cell resistance to TRAIL-induced apoptosis. Apoptosis 8: 601-607
17. Hastings MH, Reddy AB, Maywood ES (2003) A clockwork web: circadian timing in brain and periphery, in health and disease. Nat Rev Neurosci 4: 649-661
18. Hrushesky W (1985) Circadian timing of cancer chemotherapy. Science 228: 73-75
19. Innominato P, Focan C, Bjarnason GA, Garufi C, Iacobelli S, Mormont MC, Waterhouse J, Gorlia T, Marreaud S, Lévi F (2005) Quality of life (QoL) correlates with the rest/activity circadian rhythm (RAR) in patients (pts) with metastatic colorectal cancer (MCC) on first line chemotherapy with 5-fluorouracil, leucovorin and oxaliplatin: an international multicenter study (EORTC 05963) Proceedings of the 41st Annual Meeting of the American Society of Clinical Oncolory, Florida, 2005 (Abstract 8029)
20. Kaye SB (1994) Gemcitabine: current status of phase I and II trials. J Clin Oncol 12: 1527-1531
21. Lévi F (1997) Chronopharmacology of anticancer agents. In Handbook of Experimental Pharmacology. Vol: Physiology and Pharmacology of Biological Rhythms Redfern PH, Lemmer B (eds) pp 299-331. Berlin: Springer-Verlag
22. Lévi F (2001) Circadian chronotherapy for human cancers. Lancet Oncol 2: 307-315
23. Lévi F, Zidani R, Misset JL (1997) Randomized multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet 350: 681-686
24. Li XM, Metzger G, Filipski E, Boughattas N, Lemaigre G, Hecquet B, Filipski J, Lévi F (1997) Pharmacological modulation of reduced gluthatione circadian rhythms with buthionine sulfoximine: relationship with cisplatin toxicity in mice. Toxicol Appl Pharmacol 143: 281-290
25. Lund B, Hansen OP, Theilade K, Hansen M, Neijt JP (1994) Phase II study of gemcitabine (2′, 2′-difluorodeoxycytidine) in previously treated ovarian cancer. J Natl Cancer Inst 86: 1530-1533
26. Lund B, Kristjansen PEG, Hansen HH (1993) Clinical and preclinical activity of 2′, 2′-difluorodeoxycytidine (gemcitabine). Cancer Treat Rev 19: 45-55
27. Mormont MC, Waterhouse J, Bleuzen P, Giacchetti S, Jami A, Bogdan A, Lellouch J, Misset JL, Touitou Y, Lévi F (2000) Marked 24-h rest/activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and good performance status. Clin Cancer Res 6: 3038-3045
28. Peters GJ, van der Wilt CL, van Moorsel CJ, Kroep JR, Bergman AM, Ackland SP (2000) Basis for effective combination cancer chemotherapy with antimetabolites. Pharmacol Ther 87: 227-253
29. Rinaldi M, Crino L, Scagliotti GV, Mosconi AM, De Marinis F, Gridelli C, Selvaggi G, Della Giulia M, Darwish S, Porrozzi S, Novelle S, Cipri A, Bartolucci R, Calandri C, Tonato M (2000) A three-week schedule of gemcitabine-cisplatin in advanced non small cell lung cancer with two different cisplatin dose levels: a phase II randomized trial. Ann Oncol 11: 1295-1300
30. Rosado MF, Kett DH, Schein RM, Baraona FJ, Sridhar KS (2002) Severe pulmonary toxicity in a patient treated with gemcitabine. Am J Clin Oncol 25: 31-33
31. Ruiz Van Haperen VWT, Veerman G, Vermerken JB, Peters GJ (1993) 2′, 2′-Difluorodeoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cells. Biochem Pharmacol 46: 762-766
32. Sandler AB, Nemunaitis J, Denham C, von Pawel J, Cormier Y, Gatzemeier U, Mattson K, Manegold C, Palmer MC, Gregor A, Nguyen B, Niyikiza C, Einhorn LH (2000) A phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non small call lung cancer. J Clin Oncol 18: 122-130
33. Scheving LA, Jin WH (1999) Circadian regulation of uroguanylin and guanylin in the rat intestine. Am J Physiol 277 (Cell Physiol 46): C1177-C1183
34. Sothern RB, Ĺvi F, Haus E, Halberg F, Hrusheski WJ (1989) Control of a murine plasmacytoma with doxorubicine - cisplatin: dependence on circadian stage of treatment. J Natl Cancer Inst 81: 135-145
35. Swoyer J, Haus E, Sackett-Lundeen L (1978) Circadian reference values for hematologic parameters in several strains of mice. Adv Chronobiol, (Part A): 281-296
36. Tampellini M, Filipski E, Liu XH, Lemaigre G, Li XM, Vrignaud P, François E, Bissery MC, Lévi F (1998) Docetaxel chronopharmacology in mice. Cancer Res 58: 3896-3904
37. Tempero M, Plunkett W, Ruiz Van Haperen V, Hainsworth J, Hochster H, Lenzi R, Abbruzzese J (2003) Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 21: 3383-3384
38. Thomas P, Robinet G, Ferri-Dessens RM, Lena H, Gouva S, Vernejoux JM, Kleisbauer JP (2002) Phase I trial of gemcitabine and carboplatin in metastatic non-small-cell lung cancer: a Groupe Français de Pneumo-Cancerologie Study. Lung Cancer 36: 191-198
39. Tolis C, Peters GJ, Ferreira CG, Pinedo HM, Giaccone G (1999) Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines. Eur J Cancer 35: 796-807
40. UKCCCR (1998) United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasis (second edition). Br J Cancer 77: 1-10
41. van Moorsel CJ, Pinedo HM, Veerman G, Bergman AM, Kuiper CM, Vermorken JB, van der Vijgh WJ, Peters GJ (1999a) Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small cell lung cancer lines. Br J Cancer 80: 981-990
42. van Moorsel CJ, Pinedo HM, Smid K, Comijn EM, Voorn DA, Veerman G, Lakerveld B, Van der Vijgh WJ, Giaccone G, Postmus PE, Peters GJ (2000) Schedule-dependent pharmacodynamic effects of gemcitabine and cisplatin in mice bearing Lewis Lung murine non small cell lung tumours. Eur J Cancer 36: 2420-2429
43. van Moorsel CJ, Pinedo HM, Veerman G, Vermorken JB, Postmus PE, Peters GJ (1999b) Scheduling of gemcitabine and cisplatin in Lewis lung tumor bearing mice. Eur J Cancer 35: 808-814
44. Xu YZ, Plunkett W (1992) Modulation of deoxycytidylate deaminase in intact human leukemia cells - action of 2′, 2′- difluorodeoxycytidine. Biochem Pharmacol 45: 1819-1827